Co-Authors
This is a "connection" page, showing publications co-authored by NUHAD K IBRAHIM and AMAN U BUZDAR.
Connection Strength
1.108
-
Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol. 1999; 43(6):471-8.
Score: 0.168
-
Aromatase inhibitors: current status. Am J Clin Oncol. 1995 Oct; 18(5):407-17.
Score: 0.134
-
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5.
Score: 0.104
-
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 01; 13(1):228-33.
Score: 0.073
-
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85.
Score: 0.064
-
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9.
Score: 0.053
-
Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer. 2001 Feb 15; 91(4):664-71.
Score: 0.049
-
Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66.
Score: 0.048
-
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol. 2000 Dec; 11(12):1597-601.
Score: 0.048
-
Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21.
Score: 0.046
-
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000 Jan 22; 355(9200):281-3.
Score: 0.045
-
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7.
Score: 0.044
-
Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7.
Score: 0.044
-
The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 3):S30-3.
Score: 0.037
-
Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996 Apr 22; 156(8):882-8.
Score: 0.035
-
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
Score: 0.026
-
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44.
Score: 0.018
-
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 01; 23(25):5983-92.
Score: 0.017
-
Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer. 2004 Oct 01; 101(7):1508-13.
Score: 0.016
-
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71.
Score: 0.014
-
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002 Nov; 8(11):3360-8.
Score: 0.014
-
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82.
Score: 0.013